diabetes

Hua Medicine’s Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China

SHANGHAI, CHINA, Oct 10, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October... » read more

Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022

SHANGHAI, CHINA, Jun 7, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. A post-hoc analysis that involved two Phase III clinical trials... » read more

CUHK Professor Elaine Chow Receives “2022 Women’s Interprofessional Network of the American Diabetes Association Abstract Award” for Outstanding Research and Care in Diabetes

HONG KONG, Jun 5, 2022 – (ACN Newswire via SEAPRWire.com) – Professor Elaine YK Chow from the Faculty of Medicine at The Chinese University of Hong Kong has received the “2022 Women’s Interprofessional Network of the American Diabetes Association Abstract Award” in the category of Clinical Diabetes, Epidemiology, and Diabetes Complications in recognition of her... » read more

Innovative AI Technology Aids Personalized Care for Diabetes Patients Needing Complex Drug Treatment

Tokyo and Salt Lake City, Indianapolis, Mar 25, 2022 – (JCN Newswire via SEAPRWire.com) – Hitachi, Ltd. (TSE: 6501), University of Utah Health (U of U Health), and Regenstrief Institute, Inc. (Regenstrief) today announced the development of an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment. One... » read more

Hua Medicine Announces 2021 Annual Results

SHANGHAI, CHINA, Mar 17, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the “Reporting Period”). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. The New Drug... » read more

Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin

SHANGHAI, Sep 26, 2021 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (“Hua Medicine”; SEHK: 2552) today announced that at the 6th China BioMed Innovation and Investment Conference held September 25-27 in Suzhou, China (the “CBIIC”), Professor Jianhua MA, Director of the Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society,... » read more

Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China – First Glucokinase Activator (GKA) Globally

SHANGHAI, CHINA, Apr 23, 2021 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). Dorzagliatin is the first glucokinase activator (GKA) to submit... » read more

PM Lee Hsien Loong calls on global community to work together in war against diabetes

SINGAPORE – Over the past five years, Singapore’s war on diabetes has been fought on many fronts, said Prime Minister Lee Hsien Loong in a speech where he called on countries to work together and tackle the chronic disease that affects more than 420 million people worldwide. Its efforts range from stricter rules on the... » read more

Heart patients with diabetes more likely to suffer complications and death: Study

SINGAPORE – People with chronic heart disease who also have diabetes are at higher risk of death and have poorer outcomes than heart patients who do not also have diabetes, according to an international study that tracked heart patients on a registry over five years. It found that patients who had both diabetes and chronic... » read more

Hua Medicine Successfully Completes Its Registration Phase III Trials; Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin’s Phase III Combination with Metformin Trial

SHANGHAI, CHINA, Dec 18, 2020 – (ACN Newswire) – Hua Medicine (the “Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced: – Successfully completes two Phase III 53-week registration trials in over 1,200+ Chinese patients in the midst of the COVID-19 global... » read more

Brawijaya University develops the GAD65 Rapid Test Diabetes Screening Kit

Malang, East Java, Indonesia, Nov 25, 2020 – (ACN Newswire) – Brawijaya University (UB) in Malang, East Java has developed an initial screening kit for diabetes. The Bioscience Rapid Test GAD65, developed by aresearch team led by Prof. Dr. Aulanni’am, drh, DES, is ready for commercialization and use in early screening for Type I Diabetes Mellitus, before measures and... » read more